371 related articles for article (PubMed ID: 27879559)
1. Angiotensin II in Refractory Septic Shock.
Antonucci E; Gleeson PJ; Annoni F; Agosta S; Orlando S; Taccone FS; Velissaris D; Scolletta S
Shock; 2017 May; 47(5):560-566. PubMed ID: 27879559
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II in septic shock.
Jadhav AP; Sadaka FG
Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II in Decompensated Cirrhosis Complicated by Septic Shock.
Coleman PJ; Nissen AP; Kim DE; Ainsworth CR; McCurdy MT; Mazzeffi MA; Chow JH
Semin Cardiothorac Vasc Anesth; 2020 Sep; 24(3):266-272. PubMed ID: 31540560
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management.
Senatore F; Balakumar P; Jagadeesh G
Pharmacol Res; 2021 Dec; 174():105916. PubMed ID: 34597810
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock.
Chow JH; Wallis M; Lankford AS; Chancer Z; Barth RN; Scalea JR; LaMattina JC; Mazzeffi MA; McCurdy MT
Semin Cardiothorac Vasc Anesth; 2021 Mar; 25(1):67-73. PubMed ID: 32787515
[TBL] [Abstract][Full Text] [Related]
6. Broad spectrum vasopressors: a new approach to the initial management of septic shock?
Chawla LS; Ostermann M; Forni L; Tidmarsh GF
Crit Care; 2019 Apr; 23(1):124. PubMed ID: 30992045
[TBL] [Abstract][Full Text] [Related]
7. THE ROLE OF ANGIOTENSIN -2 IN THE PATHOGENESIS OF SEPTIC SHOCK DURING MULTIORGAN DYSFUNCTION SYNDROME (REVIEW).
Rurua M; Machavariani K; Sanikidze T; Shoshiashvili V; Pachkoria E; Ratiani L
Georgian Med News; 2022 Feb; (323):157-161. PubMed ID: 35271489
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.
Tsuneyoshi I; Yamada H; Kakihana Y; Nakamura M; Nakano Y; Boyle WA
Crit Care Med; 2001 Mar; 29(3):487-93. PubMed ID: 11373409
[TBL] [Abstract][Full Text] [Related]
9. Vasopressor therapy in critically ill patients with shock.
Russell JA
Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
[TBL] [Abstract][Full Text] [Related]
10. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II: a new approach for refractory shock management?
Kimmoun A; Levy B
Crit Care; 2014 Dec; 18(6):694. PubMed ID: 25645552
[TBL] [Abstract][Full Text] [Related]
12. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
[TBL] [Abstract][Full Text] [Related]
13. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock?
Carr AC; Shaw GM; Fowler AA; Natarajan R
Crit Care; 2015 Nov; 19():418. PubMed ID: 26612352
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ
Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825
[TBL] [Abstract][Full Text] [Related]
16. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
[TBL] [Abstract][Full Text] [Related]
17. Effects of vasopressin in septic shock.
Ruggiero MS
AACN Adv Crit Care; 2008; 19(3):281-7. PubMed ID: 18670203
[TBL] [Abstract][Full Text] [Related]
18. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
[TBL] [Abstract][Full Text] [Related]
20. Concomitant vasopressin and hydrocortisone therapy on short-term hemodynamic effects and vasopressor requirements in refractory septic shock.
Buckley MS; MacLaren R
J Crit Care; 2017 Dec; 42():6-11. PubMed ID: 28647651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
